CR7806A - Inhibidores de la fusion de derivados peptidos de la infeccion vih - Google Patents

Inhibidores de la fusion de derivados peptidos de la infeccion vih

Info

Publication number
CR7806A
CR7806A CR7806A CR7806A CR7806A CR 7806 A CR7806 A CR 7806A CR 7806 A CR7806 A CR 7806A CR 7806 A CR7806 A CR 7806A CR 7806 A CR7806 A CR 7806A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
fusion
hiv infection
peptide derivatives
derivatives
Prior art date
Application number
CR7806A
Other languages
English (en)
Inventor
Xie Dong
Jiang He
Original Assignee
Frontier Biotecnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Biotecnologies Co Ltd filed Critical Frontier Biotecnologies Co Ltd
Publication of CR7806A publication Critical patent/CR7806A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento se relaciona con derivados de peptidasa gp41 que son inhibidores de la infeccion viral y/o exhiben propiedades antifusogenicas. En particular, el presente invento se relaciona con derivados de gp41 que tienen actividad inhibidora contra el virus de inmunodeficiencia humana (VIH) y contra el virus de inmunodeficiencia simica (VIS) con duracion aumentada de accion para el tratamiento de las infecciones virales respectivas.
CR7806A 2002-09-24 2005-04-22 Inhibidores de la fusion de derivados peptidos de la infeccion vih CR7806A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24

Publications (1)

Publication Number Publication Date
CR7806A true CR7806A (es) 2007-09-07

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7806A CR7806A (es) 2002-09-24 2005-04-22 Inhibidores de la fusion de derivados peptidos de la infeccion vih

Country Status (15)

Country Link
US (3) US7575750B2 (es)
EP (1) EP1542718B1 (es)
JP (2) JP5385497B2 (es)
CN (1) CN1327897C (es)
AP (1) AP2203A (es)
AU (2) AU2003275116A1 (es)
BR (1) BR0314657A (es)
CA (1) CA2500248C (es)
CR (1) CR7806A (es)
EA (1) EA007918B1 (es)
ES (1) ES2558680T3 (es)
IL (1) IL167527A (es)
NZ (1) NZ539539A (es)
WO (1) WO2004029201A2 (es)
ZA (1) ZA200503118B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EA007918B1 (ru) * 2002-09-24 2007-02-27 Франтиэ Биотекнолоджиз Ко., Лтд. Пептидные производные-ингибиторы слияния при вич-инфекции
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
JP2009520469A (ja) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
CA3139341A1 (en) * 2019-05-07 2020-11-12 Frontier Biotechnologies Inc. Stable albuvirtide compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
WO1992017492A1 (en) 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
JPH11507632A (ja) * 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CA2373252C (en) * 1999-05-17 2007-08-07 Conjuchem Inc. Long lasting anti-angiogenic peptides
CN1351611A (zh) * 1999-05-17 2002-05-29 康久化学公司 病毒感染的长效融合肽抑制剂
DK1105409T3 (da) * 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
CA2501421A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting exendin-4
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
EA007918B1 (ru) * 2002-09-24 2007-02-27 Франтиэ Биотекнолоджиз Ко., Лтд. Пептидные производные-ингибиторы слияния при вич-инфекции

Also Published As

Publication number Publication date
ZA200503118B (en) 2006-11-29
NZ539539A (en) 2006-11-30
CN1327897C (zh) 2007-07-25
CN1668330A (zh) 2005-09-14
WO2004029201A3 (en) 2004-08-12
BR0314657A (pt) 2005-08-02
CA2500248C (en) 2013-03-19
US20140187476A1 (en) 2014-07-03
JP5385497B2 (ja) 2014-01-08
EA200500533A1 (ru) 2005-12-29
AU2010200823B2 (en) 2011-12-15
EP1542718A2 (en) 2005-06-22
CA2500248A1 (en) 2004-04-08
AP2203A (en) 2011-01-31
AP2005003291A0 (en) 2005-06-30
AU2003275116A1 (en) 2004-04-19
IL167527A (en) 2013-12-31
JP2010209097A (ja) 2010-09-24
WO2004029201A2 (en) 2004-04-08
EP1542718B1 (en) 2015-11-11
US8470527B2 (en) 2013-06-25
US20110003735A1 (en) 2011-01-06
AU2010200823A1 (en) 2010-03-25
US7575750B2 (en) 2009-08-18
ES2558680T3 (es) 2016-02-08
JP2006505536A (ja) 2006-02-16
US20050089840A1 (en) 2005-04-28
EP1542718A4 (en) 2011-04-06
EA007918B1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DE60216151D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CL2003001087A1 (es) Compuestos derivados de amidas de 4-alquenil piperidina de indol, azaindol y relacionadas con heterociclicos, composicion farmaceutica, util para tratar una infeccion del vih.
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
UA108250C2 (uk) Парентеральна фармацевтична композиція, її застосування та способи лікування або попередження віл-інфекції у людини
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
ES2184869T3 (es) Vacuna sub-unitaria contra la infeccion por flavivirus.
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
CL2007000380A1 (es) Compuestos derivados de pirrolo[3,4-c]pirrol sustituidos; antagonista de los receptores ccr5 de quimioquinas ccr5,composicion farmaceutica;y su uso en el tratamiento o prevencion de infecciones por virus de la inmunodeficiencia humana (vih-1)o pra tratar el sida o el arc.
ZA202306360B (en) Substituted pyridotriazine compounds and uses thereof
WO2007002172A3 (en) Hiv-1 protease inhibitors
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
DE60130641D1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
PT1476467E (pt) Imunoglobulina igg3 marcador de proteccao contra as doencas virais infecciosas e suas utilizacoes
CR20220418A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
EA202092732A1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection